However, by that same metric, most CDKN2Alow meningiomas (without any CDKN2A deletions) also had either complete loss of p16 (“0”) or minimal p16 positivity (“+1”) (n = 22, 62%). This evidence concerns the gene CDKN2A and meningioma.